<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854033</url>
  </required_header>
  <id_info>
    <org_study_id>ATRI-001</org_study_id>
    <secondary_id>U01AG024904</secondary_id>
    <nct_id>NCT02854033</nct_id>
  </id_info>
  <brief_title>Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol</brief_title>
  <acronym>ADNI3</acronym>
  <official_title>Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northern California Institute of Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Therapeutic Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
      Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
      ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been
      combined public/private collaborations between academia and industry to determine the
      relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker
      characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the
      study is to continue to discover, optimize, standardize, and validate clinical trial measures
      and biomarkers used in AD research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive,
      imaging, genetic and biochemical biomarker characteristics of the entire spectrum of
      Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild
      symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously
      funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, and ADNI-2), and remains a public/private
      collaboration between academia and industry to study biomarkers of AD. ADNI will continue to
      inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome
      measures that can be used in clinical trials, and help develop the most effective clinical
      trial scenarios.

      This is a non-randomized natural history non-treatment study. Participants will need to be 55
      - 90 years, otherwise healthy with no neurologic disease such as Alzheimer's disease.
      Approximately 1070 - 2000 participants will be enrolled at approximately 59 sites in the
      United States and Canada. Approximately, 700 - 800 will be rollover participants from
      previous ADNI studies, and 370 - 1200 will be newly enrolled. Clinical/cognitive, imaging,
      biomarker, and genetic characteristics will be assessed across the three cohorts.

      Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive
      batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral
      spinal fluid (CSF) collection for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)</measure>
    <time_frame>5 years</time_frame>
    <description>The ADAS-Cog is an in-person examiner-administered, structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs).
Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions are also obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change in cognition as measured by the Logical Memory Test I and II</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE)</measure>
    <time_frame>5 years</time_frame>
    <description>The MMSE scale evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in cognition as measured by the Cogstate Brief Battery (CBB)</measure>
    <time_frame>5 years</time_frame>
    <description>The Cogstate Brief battery (CBB) is a brief (10-15 minute) computerized cognitive battery developed by Cogstate (Cogstate Ltd. New Haven, CT, USA) that measures attention, speed of information processing, working memory and learning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in cognition as measured by the American National Adult Reading Test (ANART)</measure>
    <time_frame>5 years</time_frame>
    <description>The ANART estimates premorbid verbal intelligence (VIQ) in patients with dementia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in cognition as measured by the Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>5 years</time_frame>
    <description>The Montreal Cognitive Assessment test (MoCA) is a cognitive assessment designed to detect participants at the MCI stage of cognitive dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in cognition as measured by the Rey Auditory Verbal Learning Test</measure>
    <time_frame>5 years</time_frame>
    <description>The AVLT is a list-learning task, which assesses multiple cognitive parameters associated with learning and memory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in cognition as measured by the Trail Making Test: A and B</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tau deposition as measured by 18F-AV-1451</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amyloid deposition as measured by Florbetapir</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amyloid deposition as measured by Florbetaben</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of conversion to MCI or dementia due to AD</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of change of glucose metabolism (FDG-PET)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebral Spinal Fluid (CSF) Tau Biomarkers</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain structure using magnetic resonance imaging (MRI)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Mild Cognitive Impairment (MCI)</condition>
  <condition>Alzheimer's Disease (AD)</condition>
  <arm_group>
    <arm_group_label>Cognitively Normal (CN)</arm_group_label>
    <description>135-500 newly enrolled participants with no apparent memory problems, and 295-300 cognitively normal participants followed from the ADNI2 study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment (MCI)</arm_group_label>
    <description>150 - 515 newly enrolled participants with mild cognitive impairment (MCI), and 275-320 MCI participants followed from the ADNI2 study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Alzheimer's Disease dementia (AD)</arm_group_label>
    <description>85 - 85 newly enrolled participants with mild Alzheimer's disease (AD) dementia, and 130 - 150 mild AD participants followed from the ADNI2 study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cognitively normal (CN), mild cognitive impairment (MCI), and mild AD dementia
        participants.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (all CN participants):

          1. Participant with or without subjective memory complaints, verified by a study partner,
             beyond what one would expect for age

          2. Normal memory function documented by scoring above education adjusted cutoffs on the
             Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the
             Wechsler Memory Scale -Revised (the maximum score is 25):

               1. 9 for 16 or more years of education

               2. 5 for 8-15 years of education

               3. 3 for 0-7 years of education

          3. Mini-Mental State Exam score between 24 and 30 inclusive (Exceptions may be made for
             participants with less than 8 years of education at the discretion of the Project
             Director)

          4. Clinical Dementia Rating = 0. Memory Box score must be 0

          5. Cognitively normal, based on an absence of significant impairment in cognitive
             functions or activities of daily living

          6. Stability of Permitted Medications for at least 4 weeks:

               1. Stable doses of antidepressants lacking significant anticholinergic side effects
                  (if they are currently adequately treated for depressive symptoms and do not have
                  a history of major depression within the past 1 years)

               2. Estrogen replacement therapy is permissible

               3. Gingko biloba is permissible, but discouraged

               4. Washout from psychoactive medication (e.g., excluded antidepressants,
                  neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4
                  weeks prior to screening.

        Inclusion Criteria (all MCI participants):

          1. Participant must express a subjective memory concern as reported by participant, or
             recalled by study partner or clinician.

          2. Abnormal memory function documented by scoring below education adjusted cutoffs on the
             Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the
             Wechsler Memory Scale -Revised (the maximum score is 25):

             a. &lt; 11 for 16 or more years of education b. ≤ 9 for 8-15 years of education c. ≤ 6
             for 0-7 years of education

          3. Mini-Mental State Exam score between 24 and 30 inclusive (Exceptions may be made for
             participants with less than 8 years of education at the discretion of the Project
             Director)

          4. Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5

          5. General cognition and functional performance sufficiently preserved such that a
             diagnosis of Alzheimer's disease cannot be made by the site physician at the time of
             the Screening Visit

          6. Stability of Permitted Medications for at least 4 weeks:

               1. Stable doses of antidepressants lacking significant anticholinergic side effects
                  (if they are currently adequately treated for depressive symptoms and do not have
                  a history of major depression within the past 1 years)

               2. Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks
                  prior to Screening Visit

               3. Estrogen replacement therapy is permissible

               4. Gingko biloba is permissible, but discouraged

               5. Washout from psychoactive medication (e.g., excluded antidepressants,
                  neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4
                  weeks prior to screening.

        Inclusion Criteria (all AD participants):

          1. Participant must express a subjective memory concern as reported by participant, or
             recalled by study partner or clinician.n.

          2. Abnormal memory function documented by scoring below education adjusted cutoffs on the
             Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the
             Wechsler Memory Scale -Revised (the maximum score is 25):

               1. ≤ 8 for 16 or more years of education

               2. ≤ 4 for 8-15 years of education

               3. ≤ 2 for 0-7 years of education

          3. Mini-Mental State Exam score between 20 and 24 inclusive (Exceptions for scores of 24
             and 25 may be made for participants with less than 8 years of education at the
             discretion of the Project Director)

          4. Clinical Dementia Rating = 0.5 or 1.0

          5. NINCDS (National Institute of Neurological and Communicative Disorders and Stroke)
             -ADRDA (Alzheimer's Disease and Related Disorders Association) criteria for probable
             AD

          6. Stability of Permitted Medications for at least 4 weeks:

               1. Stable doses of antidepressants lacking significant anticholinergic side effects
                  (if they are currently adequately treated for depressive symptoms and do not have
                  a history of major depression within the past 1 years)

               2. Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks
                  prior to Screening Visit

               3. Estrogen replacement therapy is permissible

               4. Gingko biloba is permissible, but discouraged

               5. Washout from psychoactive medication (e.g., excluded antidepressants,
                  neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4
                  weeks prior to screening.

        Inclusion Criteria Specific to Newly Enrolled Participants

          1. Geriatric Depression Scale score less than 6.

          2. Age between 55-90 years (inclusive).

          3. Study partner who has frequent contact with the participant (i.e., minimum average of
             10 hours per week) and is available to accompany the participant to all clinic visits
             for the duration of the protocol.

          4. Visual and auditory acuity adequate for neuropsychological testing.

          5. Good general health with no diseases expected to interfere with the study.

          6. Participant is not pregnant, lactating, or of childbearing potential (i.e. women must
             be two years post-menopausal or surgically sterile).

          7. Willing and able to participate in a longitudinal imaging study.

          8. Modified Hachinski Ischemic Score less than or equal to 4.

          9. Completed six grades of education or has a good work history (sufficient to exclude
             mental retardation).

         10. Must speak English or Spanish fluently.

         11. Willing to undergo repeated MRIs (3Tesla) and at least two PET scans

         12. Agrees to collection of blood for genomic analysis (including GWAS (genome-wide
             association study) sequencing and other analysis), APOE (Apolipoprotein E) testing and
             biospecimen banking.

         13. Agrees to collection of blood for biomarker testing.

         14. Agrees to at least one lumbar puncture for the collection of CSF.

         15. Agrees to share genomic data and biomarker samples. Inclusion Criteria Specific to
             Rollover Participants&quot;

        The following additional inclusion criteria apply to all diagnostic categories for rollover
        participants only:

          1. Must have been enrolled and followed in ADNI-1, ADNI-GO, or ADNI-2 for at least one
             year.

          2. Willing and able to continue to participate in an ongoing longitudinal study. A
             reduced battery of tests is allowable if the participant is not able/willing to
             complete the full battery.

        Exclusion Criteria (all CN participants):

          1. Any significant neurologic disease, such as Parkinson's disease, multi-infarct
             dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor,
             progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple
             sclerosis, or history of significant head trauma followed by persistent neurologic
             deficits or known structural brain abnormalities

        Exclusion Criteria (all MCI participants):

        1. Any significant neurologic disease other than suspected incipient Alzheimer's disease,
        such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure
        hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural
        hematoma, multiple sclerosis, or history of significant head trauma followed by persistent
        neurologic deficits or known structural brain abnormalities.

        Exclusion Criteria (all AD participants):

        1. Any significant neurologic disease other than Alzheimer's disease, such as Parkinson's
        disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain
        tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple
        sclerosis, or history of significant head trauma followed by persistent neurologic deficits
        or known structural brain abnormalities.

        Exclusion Criteria (all participants):

        The following additional exclusion criteria apply to all diagnostic categories:

          1. Screening/Baseline MRI brain scan with evidence of infection, infarction, or other
             focal lesions or multiple lacunes or lacunes in a critical memory structure

          2. Subjects that have any contraindications for MRI studies, including the presence of
             cardiac pacemakers, or metal fragments or foreign objects in the eyes, skin or body.

          3. Major depression, bipolar disorder as described in DSM-IV within the past 1 year.
             Psychotic features, agitation or behavioral problems within the last 3 months that
             could lead to difficulty complying with the protocol.

          4. Currently treated with medication for obsessive-compulsive disorder or attention
             deficit disorder.

          5. History of schizophrenia (DSM IV criteria).

          6. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV
             criteria).

          7. Any significant systemic illness or unstable medical condition, which could lead to
             difficulty complying with the protocol.

          8. Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that
             might interfere with the study. A low B12 is exclusionary, unless follow-up labs
             (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not
             physiologically significant.

          9. Residence in a skilled nursing facility.

         10. Current use of specific psychoactive medications (e.g., certain antidepressants,
             neuroleptics, chronic anxiolytics or sedative hypnotics). Current use of warfarin or
             other anticoagulants such as dabigatran, rivaroxaban and apixaban (exclusionary for
             lumbar puncture).

         11. Current use of any other exclusionary medications

         12. Investigational agents are prohibited one month prior to entry and for the duration of
             the trial.

         13. Participation in clinical studies involving neuropsychological measures being
             collected more than one time per year.

        Exclusion Criteria Specific to AV-1451 PET:

        The following criteria are exclusionary only for the AV-1451 scanning portion of the study:

          1. History of risk factors for torsades de pointes (a cardiac dysrhythmia associated with
             sudden death) or taking medications known to prolong the QT interval. A list of
             restricted medications will be provided.

          2. Have an ECG obtained prior to the AV-1451 PET scan that in the opinion of the
             investigator is clinically significant with regard to the subject's participation in
             the study. Bazett's corrected QT (QTcB) interval must be evaluated and must not exceed
             458 msec in males, or 474 msec in females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W. Weiner, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Aisen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC Alzheimer's Therapeutic Research Institute (ATRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Peterson, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ADNI Central Phone Number</last_name>
    <phone>888-2-ADNI-95 (888-223-6495)</phone>
    <email>adni3-participate@usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Vaughn</last_name>
      <phone>205-996-3679</phone>
      <email>jhvaughn@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Geldmacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Hetelle</last_name>
      <phone>602-839-4893</phone>
      <email>Joel.Hetelle@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Allison Perrin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelica Garcia</last_name>
      <email>angelica.garcia@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Marwan Sabbagh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherye Sirrel</last_name>
      <phone>623-832-6522</phone>
      <email>sherye.sirrel@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Edward Zamrini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Yañez</last_name>
      <phone>949-824-3250</phone>
      <email>byanez@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Gaby Thai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>920371707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Vanderswag</last_name>
      <phone>858-249-0556</phone>
      <email>hvanderswag@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>James Brewer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Beach VA Neuropsychiatric Research Program</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sakineh (Parvin) Khalaghizadeh</last_name>
      <phone>562-826-8000</phone>
      <phone_ext>23393</phone_ext>
      <email>sakineh.khalaghizadeh@va.gov</email>
    </contact>
    <investigator>
      <last_name>Steven Potkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900335310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Diaz</last_name>
      <phone>323-442-7600</phone>
      <email>Nadine.Diaz@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Lon Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mather Craig</last_name>
      <phone>310-794-6191</phone>
      <email>mmcraig@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Kremen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine - Neuropsychiatric Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>928683298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto HSC / Stanford School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Taylor</last_name>
      <phone>650-493-5000</phone>
      <phone_ext>6+63102</phone_ext>
      <email>joyt@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jerome Yesavage, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>945985900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongzheng Zhang</last_name>
      <phone>925-357-6914</phone>
      <email>hzzhang@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>John Olichney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>65103330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srinath Ramanan</last_name>
      <phone>203-764-6797</phone>
      <email>srinath.ramanan@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher van Dyck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>200072145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Mallory (Poe)</last_name>
      <phone>202-687-3355</phone>
      <email>jp1715@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Brigid Reynolds, RN, MSN, NP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>200600001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Wolday</last_name>
      <phone>202-865-7895</phone>
      <email>swolday@howard.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Obisesan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sochenda Chea</last_name>
      <phone>904-953-3234</phone>
      <email>chea.sochenda@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Neill Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wien Center for Clinical Research</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>331402877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Greig-Custo</last_name>
      <phone>305-674-2121</phone>
      <phone_ext>54480</phone_ext>
      <email>Maria.Greig-Custo@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Duara Ranjan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Health Byrd Alzheimer Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>336134808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juris Janavs</last_name>
      <phone>813-396-0637</phone>
      <email>jjanavs@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Byram</last_name>
      <phone>404-712-0195</phone>
      <email>rbyram@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Allan Levey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606113010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Lipowski</last_name>
      <phone>312-503-2486</phone>
      <email>k-lipowski@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Rogalski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606123806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Tharpe</last_name>
      <phone>312-563-4721</phone>
      <email>Rita_Tharpe@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Raj Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Herring</last_name>
      <phone>317-963-7418</phone>
      <email>sherring@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Farlow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ekstam-Smith</last_name>
      <phone>319-353-5158</phone>
      <email>karen-ekstam@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Delwyn Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Dodd</last_name>
      <phone>913-945-6792</phone>
      <email>mdodd@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Burns, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>405042681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothy Ross</last_name>
      <phone>859-323-2737</phone>
      <email>dross3@email.uky.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212242764</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel D'Agostino II</last_name>
      <phone>410-502-6161</phone>
      <email>ddagost1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Marilyn Albert, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>21155804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Coppelman</last_name>
      <phone>617-732-8085</phone>
      <email>ncoppelman@partners.org</email>
    </contact>
    <investigator>
      <last_name>Gad Marshall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>21182307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Gullotti</last_name>
      <phone>617-414-1077</phone>
      <email>ngullott@bu.edu</email>
    </contact>
    <investigator>
      <last_name>Ron Killiany, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Ann Arbor</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>481052967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Zbizek-Nulph</last_name>
      <phone>734-232-1199</phone>
      <email>lzbizek@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Judith Heidebrink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>559050001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Albers</last_name>
      <phone>507-293-4866</phone>
      <email>Albers.Colleen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Peterson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University, St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>631082215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Oliver</last_name>
      <phone>314-286-2683</phone>
      <email>olivera@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Beau Ances, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>891060100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Bjorklund</last_name>
      <phone>702-483-6036</phone>
      <email>girbink@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Charles Bernick, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Eglow</last_name>
      <phone>518-264-1130</phone>
      <email>eglowm@mail.amc.edu</email>
    </contact>
    <investigator>
      <last_name>David Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>142261727</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Kumm</last_name>
      <phone>716-558-3492</phone>
      <email>ckumm@dentinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Horacio Capote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100166055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anaztasia Ulysse</last_name>
      <phone>212-263-0771</phone>
      <email>Anaztasia.Ulysse@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Martin Sadowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100296552</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Greenberg</last_name>
      <phone>212-659-5621</phone>
      <email>jonathan.greenberg@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Hillel Grossman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Perez-Vivaldo</last_name>
      <phone>212-342-0522</phone>
      <email>cap2238@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Yaakov Stern, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nathan Kline Institute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>109621159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antero Sarreal</last_name>
      <phone>845-398-6532</phone>
      <email>asarreal@nki.rfmh.org</email>
    </contact>
    <investigator>
      <last_name>Nunzio Pomara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Kowalski</last_name>
      <phone>585-760-6569</phone>
      <email>nancy_kowalski@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Anton Portseinsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cammie Hellegers</last_name>
      <phone>919-681-3986</phone>
      <email>caroline.hellegers@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Murali Doraiswamy, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Gordineer</last_name>
      <phone>336-713-8477</phone>
      <email>lgordine@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Jeff Williamson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>441224312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parianne Fatica</last_name>
      <phone>216-464-6474</phone>
      <email>parianne.fatica@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Alan Lerner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Icenhour</last_name>
      <phone>614-293-6882</phone>
      <email>jennifer.icenhour@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Scharre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>972393011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrica DiMicco</last_name>
      <phone>503-494-0976</phone>
      <email>dimicco@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Silbert, MD, MCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Nunez</last_name>
      <phone>215-662-4379</phone>
      <email>Jessica.Nunez@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>David Wolk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryAnn Oakley</last_name>
      <phone>412-692-2721</phone>
      <email>oakleym@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Oscar Lopez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sierra Irizarry</last_name>
      <phone>401-444-2421</phone>
      <email>sierra.irizarry@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Brian Ott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital Memory and Aging Program</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Tang</last_name>
      <phone>401-455-6403</phone>
      <email>TTang@Butler.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Salloway, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Lapp</last_name>
      <phone>843-724-2214</phone>
      <email>allison.lapp@rsfh.com</email>
    </contact>
    <investigator>
      <last_name>Abigail OConnell, MS APRN FNP-C</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Ross</last_name>
      <phone>615-875-0955</phone>
      <email>sally.ross@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Newhouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern MC at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Knowles</last_name>
      <phone>214-648-0563</phone>
      <email>Patricia.knowles@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle Womack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nat Pacini</last_name>
      <phone>713-798-5328</phone>
      <email>nat.pacini@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Kass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Garrett</last_name>
      <phone>713-441-9484</phone>
      <email>jmgarrett@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Masdeu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>537920001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Harding</last_name>
      <phone>608-262-4760</phone>
      <email>sjharding@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Sterling Johnson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, Clinic for AD &amp; Related</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph's - Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene Bartha</last_name>
      <phone>519-685-4292</phone>
      <phone_ext>42286</phone_ext>
      <email>Charlene.Bartha@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Finger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Center - Cognitive Neurology</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 4R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryna Butenko</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>6108</phone_ext>
      <email>maryna.butenko@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Sandra Black, OC, O.Ont., MD, FRSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital Memory Clinic</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Hosein</last_name>
      <phone>514- 340-8222</phone>
      <phone_ext>23621</phone_ext>
      <email>chosein@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Howard Chertkow, M.D., F.R.C.P.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://adni-info.org</url>
    <description>Alzheimer's Disease Neuroimaging Initiative</description>
  </link>
  <link>
    <url>http://adni.loni.usc.edu/</url>
    <description>Laboratory of Neuro Imaging (LONI)</description>
  </link>
  <link>
    <url>http://atri.usc.edu/studies/</url>
    <description>Alzheimer's Therapeutic Research Institute</description>
  </link>
  <link>
    <url>http://www.nia.nih.gov/alzheimers</url>
    <description>Alzheimer's Disease Education and Referral Center</description>
  </link>
  <link>
    <url>http://adni-info.org/Scientists/ADNIScientistsHome/ADNIPublications.html</url>
    <description>List of Alzheimer's Disease Neuroimaging Initiative Publications</description>
  </link>
  <link>
    <url>http://www.brainhealthregistry.org/</url>
    <description>Brain Health Registry (BHR)</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Aisen</investigator_full_name>
    <investigator_title>Director, Alzheimer's Therapeutic Research Institute</investigator_title>
  </responsible_party>
  <keyword>amyloid</keyword>
  <keyword>plaques</keyword>
  <keyword>neuroimaging</keyword>
  <keyword>biomarkers</keyword>
  <keyword>cognition disorder</keyword>
  <keyword>early detection</keyword>
  <keyword>pre-dementia</keyword>
  <keyword>dementia</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>tau</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

